Cramer: Focus on Strong Companies Like Eli Lilly, Not Macro Trends

Jim Cramer advises investors not to focus solely on macroeconomic trends like employment data or interest rates. He highlights Eli Lilly's blowout quarter, where the company reported $11.30 billion in revenue and $3.92 EPS, far exceeding expectations. Shares rose 9.5% after the report.

Cramer emphasizes that $Eli Lilly and Co (LLY.US)$ 's success is due to strong drug formulations and manufacturing capabilities, not macro factors. He recommends investing in solid companies and holding shares as long as the business remains strong.